Helicobacter pylori infection and ischemic heart disease: could experimental data lead to clinical studies? by Ribaldone, Davide Giuseppe et al.
Helicobacter pylori infection and ischemic heart disease:  
Could experimental data lead clinical studies? 
 
 
Davide Giuseppe Ribaldone1*, Sharmila Fagoonee2*, Ingrid Hickman3, Fiorella Altruda4, Giorgio 
Maria Saracco1,3, Rinaldo Pellicano1 
 
 
1 Unit of Gastroenterology, Molinette Hospital, Turin, Italy  
2 Institute for Biostructures and Bioimages (CNR) c/o Molecular Biotechnology Center, University 
of Turin, Turin, Italy                                                                                    
3 Department of Nutrition and Dietetics, Princess Alexandra Hospital, Woolloongabba, Australia 
4 Molecular Biotechnology Center, University of Turin, Turin, Italy       
3Department of Oncology, University of Turin, 10123 Turin, Italy.   
 
*Equally contributed to this work. 
 
Corresponding author: Rinaldo Pellicano, MD, Unit of Gastroenterology, Molinette-SGAS Hospital, 
Via Cavour 31, 10126 Turin, Italy. E-mail: rinaldo_pellican@hotmail.com    
 
 
Running title: Helicobacter pylori and Ischemic Heart Disease
2 
 
Abstract 
Despite the remarkable advances made in primary prevention and treatment, ischemic heart disease (IHD) 
remains the leading cause of death and a significant cause of disability in developed countries. Since 
traditional cardiovascular risk factors failed to predict all cases of IHD, there is an intensive research to 
explore other potential etiologic factors. Among these, numerous studies have considered the theoretical 
link between IHD and chronic infections, including Helicobacter pylori (H. pylori). Considering that 
epidemiologic studies have produced conflicting results, due to geographical variations of IHD and H. 
pylori prevalence as well as heterogeneity of study designs, an alternative way to analyze this topic is to 
assess if consistency for a biological plausibility exists. In this review we critically analyzed the 
experimental data on this topic, to assess whether their results could lead future clinical studies. 
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Introduction 
   An impressive decline in mortality due to acute ischemic heart disease (IHD) has occurred in the last 50 
years. This has been attributed to improvement in primary prevention and to major progress made in 
treatment.1 Despite these remarkable advances, IHD remains the leading cause of death in developed 
countries2 and the responsible for sudden cardiac death in postmyocardial-infarction patients.3  Moreover, 
it occupies a significant position among the main causes of human disability.4  
   Since traditional cardiovascular risk factors consistently predict some but not all cases of IHD (about 
20% of acute events occur in the absence of such factors), emerging risk factors are being explored.5 In 
the last few decades many studies across several fields have explored the potential link between IHD and 
chronic infections6-8, including Helicobacter pylori (H. pylori). Considering that epidemiologic studies 
have produced conflicting results, due to geographical variations of IHD and H. pylori prevalence as well 
as to heterogeneity of study designs 9-13, an alternative way to analyze this topic is to assess if a consistent 
biological plausibility exists. The aim of this review is to focus on experimental data obtained by 
investigating the relationship between H. pylori and IHD. This will be critically reviewed in 3 sections: 1) 
the bacterium, 2) the experimental findings both in the animal models and in humans 3) the potential 
clinical implications. 
 
The bacterium 
   H. pylori is a gram negative spiral-shaped bacterium usually acquired during childhood.14 The infection 
persists for years, often for a lifetime. Since the human stomach is an unfriendly place for most bacteria, 
in order to live in the gastric environment, H. pylori has developed a repertoire of acid resistance 
mechanisms. To colonize gastric mucosa, it penetrates the mucous layer through the acidic environment 
of the stomach (pH < 2) and to overcome this barrier the bacterium produces the enzyme urease, which 
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degrades urea to ammonia in the gastric epithelium. The excess of ammonia raises the pH neutralizing 
gastric acid and thereby allowing H. pylori to safely traverse the mucus layer to the epithelium surface.15 
   Currently, it is estimated that around half of the world population is infected with H. pylori. This 
bacterium is accepted as the most important cause of gastritis and peptic ulcer (PU) and a risk factor for 
gastric cancer.16 Moreover, in the last few decades, several studies have reported on the link between 
chronic H. pylori infection and a variety of extragastric manifestations,17 based on potential mechanisms 
involving a low-grade inflammatory state, molecular mimicry patterns, and interference with the 
absorption of nutrients.18,19 Although the Maastricht IV/Florence Consensus Report of the European 
Helicobacter Study Group has considered causal associations of H. pylori  in those with unexplained iron-
deficiency anemia, idiopathic thrombocytopenic purpura (Grade A recommendation) and vitamin B12 
deficiency (Grade B recommendation), other relationships could not be excluded.20 The major interest to 
deeply research in this field is that the cure of the infection, consisting in a multidrug regimen based on 
antisecretive agents and antibiotics21, is relatively easy and far less expensive than long-term treatment of 
either known risk factors for IHD or therapy for the acute events and the secondary prevention of IHD. 
 
Experimental findings  
   Atherosclerosis is the principal underlying cause of IHD. As a general principle in the pathogenesis of 
most IHD cases, the epicardial coronary occlusion from atherosclerosis should be considered. Hence, the 
ischemic damage is almost always the result of an imbalance between supply and demand. Coronary 
atherosclerosis progress through stages of fatty-streak deposition in coronary arteries to development of 
fibro-fatty plaque, with the increase in size until it causes partial or total luminal obstruction. At any 
stage, the atherosclerotic lesion may be vulnerable to erosion or rupture, thereby exposing the 
subendothelial vessel wall to substances in the circulating blood. Vulnerable plaques have evidence of 
inflammation, with monocytes, macrophages, and sometimes T-cell infiltrates22, together with thin 
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fibrous caps, derived from smooth muscle cells, which migrate from the media into the intima, and large 
lipid cores, released from necrotic foam cells monocyte-macrophages which migrate into the intima and 
ingest lipids. The inflammatory milieu in atherosclerosis is further exaggerated and sustained by the 
innate immune system involving T-cell activation.23 Elevated bloodstream levels of the acute-phase 
proteins, such as C-reactive protein (CRP) and proinflammatory cytokines, in patients with cardiovascular 
events, provide more evidence suggesting the role of inflammatory processes.24,25 Procoagulating factors 
reside within the plaque and, in the absence of counter-balancing antithrombotic factors and fibrinolytic 
activities within the endothelial cells, can lead to thrombosis.26  
   Whether and when H. pylori has a role in this multistep process has been investigated by several studies 
which are summarized and grouped on the basis of the main mechanism explored: 
Studies on platelet aggregation and coagulation parameters 
   The issue of the role of infectious agents in recruiting platelets into thrombus has been widely 
examined.27 Platelets derive from megakaryocite cytoplasm, and on activation change from the normal 
disc shape to a compact sphere with dendritic extension facilitating adhesion. Platelets are the first blood 
cells to arrive at the site of endothelial activation. By its glycoproteins (GPs) Ib and IIb/IIIA these cells 
engage surface molecules on the endothelium, which contributes to endothelial cell activation. Once 
activated, these cells express several types of leukocyte adhesion molecules, which can cause blood cell 
rolling along the vascular surface to adhere to the site of activation.28 This step might play an important 
role in platelet aggregation leading to plaque vulnerability and eliciting acute ischemic events. Hence, the 
speculation that H. pylori infection could induce platelets and immune activation mediated by cytokines, 
such as interleukin (IL)-1, IL-6 and tumor necrosis factor (TNF)-α (Figure 1).9  
   It has been reported that some strains of H. pylori (namely 60190, 60190 VacA- and Tx30a) bound von 
Willebrand factor (vWF), a large multimeric GP (the basic vWF monomer is a 2050-amino acid protein), 
and interacted with GPIb to induce platelets aggregation in humans. Such aggregation was inhibited 
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completely by aspirin, GP IIb/IIIa antagonists and monoclonal antibodies, that prevented the vWF 
interaction with GPIb. Aggregation also required immunoglobulin G (IgG) directed against H. pylori and 
could be inhibited by an antibody to the platelets IgG receptor (FcγRIIA).29 Moreover, studying 
endothelial function parameters, it has been shown that in patients with unstable angina and seropositivity 
to both H. pylori and Chlamydia pneumonia (C. pneumonia), antigenic kind of H. pylori was significantly 
correlated with an increased plasma concentration of vWF and plasminogen activator inhibitor type 1 
(PAI-1).30 The latter is a serine protease inhibitor (serpin) associated with elevated IHD risk.31 However, 
another study did not find significant differences in platelet activation (measured also by P-selectin 
plasma level) or in inflammatory parameters after H. pylori eradication, in patients with recent acute 
coronary syndrome; nevertheless, cardiovascular events recurred in significantly less patients in whom 
the bacterium was absent or eradicated compared with subjects with persisting infection (p = 0.01).32 In 
mice, H. pylori infection promoted the genesis of platelet aggregates. In particular, the bacterium evoked 
both marked increase in the flux of rolling leukocytes and the appearance of platelet and leukocyte-
platelet aggregates in murine gastric venules; this process was abrogated by antibodies against L- or P-
selectin.33 The former participates in leukocytes rolling on the vessel wall as well as in the extravasation 
process during inflammation. The latter is an adhesion molecule restricted to the vascular system where it 
mediates the initial attachment of leukocytes to endothelial cells.34 The same authors showed that 
circulating platelet aggregates and activated platelets were detected in 5 out of 5 H. pylori infected versus 
none uninfected humans.33 Similar results were obtained by others groups.35 Aguejouf et al. showed that, 
by damaging the mesenteric arteriole endothelium by Argon laser pulses, there was a significant increase 
in the number of platelet emboli (p < 0.001) and in the duration of embolization in mice chronically 
infected with H. pylori versus controls. A significant difference was also found in the fibrinogen levels 
between infected and uninfected mice.36 Thus, on the basis of the available data, there are convergent 
evidences both in humans and in animal models that H. pylori could elicit platelet aggregation.37 
7 
 
   The importance of finding increased thrombin generation rate and correlation of plasma prothrombin 
fragment 1+2 (comprising the first 271 residues of prothrombin) and TNF-α levels with H. pylori 
infection is uncertain, as these data have been obtained in subjects without IHD.38 However, since 
thrombin plays a central role in haemostasis and thrombosis as well as in platelet function, fibrinolysis 
and vascular cell function39, this issue is of paramount importance. Furthermore, the evidence that, after 
H. pylori eradication, fragment 1+2 and TNF-α levels decreased (p < 0.05) to the threshold observed in 
controls, suggests a potential role of the bacterium in the activation of the clotting system.38   
   Fibrinogen, a soluble 340 kDa plasma glycoprotein, is the ligand for GP IIb/IIIa to mediate platelet 
aggregation. Plasma fibrinogen is a well-known independent risk factor for arterial thrombotic disorders. 
40 While some groups have reported a high level of fibrinogen in H. pylori infected patients41,42, other 
studies failed to do so.37,43 In a single-blind, randomized, prospective study, it has been shown that 
treatment for H. pylori and C. pneumoniae infections decreased fibrinogen plasma level (p < 0.001) in 
patients with IHD.44 In a previous work, on H. pylori-positive patients with dyspepsia and/or PU, 
followed up for 5 years, fibrinogen decreased in a significant manner (p < 0.0001) after bacterial 
eradication (from 257 to 222 mg/dL).45 Similar results were obtained by Yusuf and Mishra in elderly IHD 
subjects46 and Ando et al., who found, one year after eradication, a statistically significant fall in 
fibrinogen level that persisted throughout the 3 years’ follow-up.47 This contrasts with the findings of 
Elizalde et al., who reported the benefit in preventing recurrence, after H. pylori eradication, in patients 
with acute coronary syndrome but failed to evidence a difference in plasma fibrinogen levels (p = 0.8).32 
Studies on the immune response and antigen mimicry 
   The persistence of a chronic, low-grade inflammation, provides a vital clue for infectious pathogenesis 
of IHD. Chronic H. pylori infection induces a pro-inflammatory state, resulting into an increase in 
cytokines levels such as TNF-α, IL-1, IL-6, IL-8, γ interferon and soluble molecules like intercellular 
adhesion molecule (ICAM-1) and vascular cell adhesion molecule (VCAM-1). Furthermore, H. pylori 
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eradication leads to a reduction in cytokine levels.48 The cytokines secreted by activated inflammatory 
cells can stimulate the endothelium, transforming its antiadhesive and anticoagulant properties into 
adhesive and procoagulant properties. Since dysfunction of endothelial cells is probably the earliest event 
in the process of lesion formation, the assessment of endothelial function may be a useful tool to better 
understand the physiopathology. But, is it possible that H. pylori participates in the genesis or in the 
consequences of endothelial dysfunction? Moreover, is this immune response able to maintain a pattern of 
chronicity? Some answers came from an elegant study conducted by Hatz et al. on gastric specimens. 
Considering that a prerequisite for trans-endothelial migration of leucocytes into the lamina propria of 
gastric mucosa is the primary adhesion of these cells to activated endothelium, the authors have shown 
that H. pylori was able to favor leukocyte-endothelial adhesion by increasing ICAM-1 and VCAM-1 
levels.49 Hence, whether the bacterium would be involved in extragastric manifestations such as IHD, the 
latter could be the consequence of a long-term inflammatory stimulus leading to a continual interaction 
between leukocyte and endothelial cells.  
   Strains of H. pylori are genetically diverse and have been divided into type I and type II according to 
the expression or not of cytotoxin-associated gene A (CagA) protein, which is encoded on the cag 
pathogenicity island.50 The potential role of the more virulent H. pylori strain, named CagA+, in the 
pathogenesis of IHD, has been investigated in epidemiological studies, with controversial outcomes.51-54 
From an experimental point of view, the ability of these strains to induce gastric epithelial IL-8 mRNA 
expression and IL-8 protein secretion results in neutrophil chemotaxis and activation with oxidative burst 
as an important pathogenetic factor. Thus, an intense immune response against CagA+ H. pylori strains 
might play a role in the acute events of IHD.55 Franceschi et al., in an experimental study, have shown 
that anti-CagA antibodies reacted with cytoplasm and nuclei of smooth muscle cells in umbilical cord and 
atherosclerotic vessel sections, cytoplasm of fibroblast-like cells in intimal atherosclerotic plaques, and 
the cell membranes of endothelial cells. Anti-CagA antibodies also specifically immunoprecipitated two 
high molecular weight antigens of 160 and 180 kDa from both normal and atherosclerotic artery lysates. 
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56 However, several studies have denied a higher prevalence of these strains in the case of IHD9 and one 
has observed a significantly lower risk of cardiovascular mortality in subjects infected with H. pylori 
CagA+ strains.57 One speculative assertion might be that a constant stimulation of the immune system, in 
turn, might protect H. pylori-infected individuals from other acute infections that increase the risk of 
cardiovascular mortality.58.59 Thus, the activation of the immune system alone by H. pylori may not be a 
sufficient pathogenetic mechanism able to induce the acute phase of IHD.  
   It is well-known that pathogen-triggered autoimmunity plays a role in early atherosclerosis, as 
antibodies to mycobacterial heat shock proteins (HSP)65 are associated with elevated levels of coronary 
calcification and correlate with H. pylori infection.60 The lipopolysaccharide (LPS) of many H. pylori 
strains displays antigens similar to that of humans, such as Lewis x and y (the so-called antigen mimicry), 
which could induce antibodies that cross react with host tissues. This has been shown in humans, 
comparing anti-HSP60 levels in IHD patients and controls, and noticing that IgG level to HSP60 was 
more increased in the former than in the latter group.61 Moreover, in a subset of patients with unstable 
angina, an intense immune response, for example against CagA+, might act as a trigger for the 
precipitation of coronary instability via a molecular mimicry mechanism. Antibodies to CagA protein can 
act as autoimmune ones due, as described above, to cross-reactivity with the cytoplasm and the nuclei of 
myocytes existing in the coronary artery wall and cytoplasm of fibroblast-like cells in atherosclerotic 
plaques. Antigenic mimicry, such as immunological cross-reactivity between bacterial and HSPs, can lead 
to coronary calcification and early atherosclerosis. It has been shown that H. pylori HSP60, a 60 kDa 
oligomer composed of monomers that form a complex, arranged as two stacked heptameric rings, induced 
a specific T-helper 1 immune response associated with the progression of atherosclerosis in animal 
models.62 To reinforce these data there was evidence that H. pylori eradication significantly reduced the 
progression of atherosclerosis in infected mice9 and led to a significant fall in anti-HSP65 titres in patients 
with coronary atherosclerosis.63   
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Studies on atherosclerotic-related patterns 
      The link between H. pylori and atherosclerosis has been extensively explored by indirect (serological 
research for markers of metabolic alterations or systemic inflammation) and direct (bacterial research on 
the plaque) studies. Several researches have shown that H. pylori may induce atherogenesis though a low-
grade persistent inflammatory stimulation64,65; however, other studies did not support this finding.66 The 
potential implication of H. pylori into causing an atherogenic modified profile has been studied too. 
Based on some data, the levels of total cholesterol and low-density lipoprotein (LDL)67 as well as of 
triglycerides68 were increased in patients infected with H. pylori. Other studies showed lower high-density 
lipoprotein (HDL) cholesterol levels in H. pylori-infected patients compared to controls.69 Huang et al. 
reported that more serious coronary atherosclerosis was observed in patients infected with H. pylori 
CagA+ strains: in this case, the levels of total cholesterol, LDL, apolipoprotein B, CRP, oxidized LDL 
(oxLDL) were significantly elevated.70 Some authors have proposed that the higher levels of cholesterol 
in H. pylori-infected patients may be a protective bacterial factor since it could enhance H. pylori 
resistance against antibiotic therapy.71 The issue of the change in lipid profile after H. pylori eradication 
has been explored. An improvement has been obtained by some45 but not all groups.9 These results, 
although equivocal, suggest that H. pylori infection in different populations could be associated either 
with elevated total cholesterol or LDL and lower HDL and apolipoprotein A and B. The same 
consideration can be applied to triglycerides.48  
   The convergent role of inflammatory and metabolic pathways, stimulated by oral infection with H. 
cinaedi (a nongastric emerging H. species), in the pathogenesis of atherosclerotic plaque has been shown 
by Khan et al., who found that this infection significantly enhanced atherosclerosis in hyperlipidaemic 
mice. Aortic root lesions in infected mice showed increased accumulation of neutrophils and foam cells, 
which was due, at least partly, to bacteria-mediated increased expression of proinflammatory genes. 
Although the mice were asymptomatics, the detection of cytolethal distending toxin RNA of H. cinaedi 
indicated aorta infection. Moreover, H. cinaedi infection altered expression of cholesterol receptors and 
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transporters in cultured macrophages and caused foam cell formation. Also, infection induced 
differentiation of THP-1 monocytes into macrophages.72    
   Coronary artery calcium (CAC) levels reported by computer tomography scans are widely accepted as 
reproducible and reliable markers for IHD risk.73 One study found that seropositivity for H. pylori IgG 
was significantly related to the presence of CAC.74 This suggests that the bacterium could play a role in 
early atherosclerosis. The limitation of this study is due to the gap between H. pylori seropositivity and 
the possibility that this reflects a true infection.75 A prospective, serological study on 5744 individuals, 
found that none of the five pathogens investigated or their accrual was associated with CAC incidence 
and progression.76 
   The fact that H. pylori DNA was identified in atherosclerotic plaques of patients with severe CHD 
would support the hypothesis of the association.77 Some studies, using the polymerase chain reaction 
(PCR) technique have shown that a substantial proportion of coronary atherosclerosis plaques were 
colonized by H. pylori.78-80 Kowalski et al. found 47.8% versus 0% of H. pylori DNA in coronary artery 
of patients with and without IHD, respectively.77 Adiloglu et al., searching for H. pylori DNA in 
atherosclerotic plaques of 14 coronary endarterectomy specimens, detected it in 3 out of 14 specimens 
(21.4%) versus one out of 15 (6.7%) in the control group (left internal mammarian artery samples without 
any plaques). The difference was not statistically significant. With regard to the level of CRP, 
apolipoprotein B and IL-6, no significant difference was shown between H.pylori DNA positive and 
negative subjects. However, both CRP and IL-6 levels were higher in case of positivity.81 These findings 
“revitalize” the question of the possible existence of the bacterium in the plaque and on its role. 
Revisiting the literature, H. pylori genomic material has been detected in the plaque only in sporadic 
occasions, in contrast to C. pneumoniae, the other agent often implicated in the pathogenesis of IHD. 
78,82,83 Hence, due to the rarity of findings supporting a “direct” mechanism, the involvement of H. pylori 
via an indirect pathway has been proposed.75 
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Studies on homocysteinemia involvement 
   Chronic H. pylori infection strongly increases the risk of chronic atrophic gastritis.84 Once the latter is 
present, gastric mucosa functions are impaired resulting in a reduced secretion of pepsinogen I (PGI) and 
II (PGII) and malabsorption of essential metabolites like vitamin B1285, a condition accompanied with 
high serum homocysteine levels.86 The increased pH of the gastric juice and the decrease of ascorbic acid 
levels lead to a reduced folate absorption. Low folate hampers the methionine synthase reaction 
determining an increased concentration of homocysteine in the blood. The last step, in the proposed 
causal pathway from H. pylori and chronic atrophic gastritis to coronary artery disease, is the impact of 
homocysteinemia, which induces damage to endothelial cells, atherosclerosis and finally, IHD.87 
Moreover, it has been reported that there may be an association between slow coronary flow, decreased 
plasma folate levels and increased homocysteinemia. This is interesting considering that the prevalence of 
H. pylori is increased in patients with slow coronary flow and there is a significant correlation between 
the former and folate reduction.88 
 
Potential clinical implications 
   Several reports have demonstrated that antibiotic therapy can reduce relapse and mortality after an 
episode of acute myocardial infarction89,90, thereby reinforcing the hypothesis of a link between bacterial 
infections and IHD.91 Although encouraging, these data have been obtained from small pilot studies.89,90 
A double-blind, randomised, placebo-controlled trial, aimed to determine in patients with myocardial 
infarction or unstable angina whether antibiotics active against C. pneumoniae and H. pylori had 
beneficial effects on the development of cardiac death or re-admission with acute myocardial infarction or 
unstable angina. After 12 weeks, the proportion of patients treated with antibiotic regimen experienced an 
endpoint was 17.2% as compared with 27.2% in the placebo group (p < 0.02). By 52 weeks, these 
respective proportions were 25.8% and 38.9% (p < 0.02). There was no significant difference in total 
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mortality. The beneficial effect of antibiotics on cardiac events was independent of either H. pylori or C. 
pneumonia status. The authors concluded that the design of the trial did not allow conclusions to be 
drawn regarding the mechanism responsible for the positive effects observed.92 Opposite results were 
obtained by the ANTIBIO Study, which did not observe a reduction in event rate 12 months after 
treatment with roxithromycin, in patients with acute myocardial infarction.93 
   Considering these controversial data, the need for extensive studies with appropriate epidemiological 
and clinical approaches is evident, to investigate a potential causal relationship between H. pylori 
infection and IHD. These should be prospective and randomised intervention trials, based on 
antimicrobial treatment and long-term follow-up for cardiovascular events, to evaluate an eventual 
delayed benefit. How might experimental data lead clinical studies? In this direction, experimental 
models could help to define under which conditions these trials should be performed. It may be that the 
optimal population would include patients with atherosclerosis and H. pylori infection, to assess if 
bacterial eradication could prevent the progression of a silent IHD or the trigger of an acute cardiac event. 
Nevertheless, the inclusion of patients with a previous history of acute myocardial infarction, would 
permit to assess if bacterial eradication could reduce its recurrence rate.94,95 Obviously, the latter strategy 
should be applied considering the standard cardiology treatment. It is more exciting, but improbable, the 
possibility to assess if H. pylori eradication could induce a benefit in terms of primary prevention, in 
subjects without cardiovascular abnormalities. Moreover, since at least in the animal model a relationship 
between intestinal microbiota and myocardial infarction has been shown96, and considering that the 
human bowel is the largest reservoir of microbes (it contains trillions of bacteria)97 in the body, with 
remarkable relevance for the human health98, this should be accompanied with the modulation of the 
physiologic intestinal microbiota. 
Conclusions 
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   Although currently available data do not prove in an unequivocal manner the role of H. pylori infection 
in the pathogenic mechanism of CHD, any potential relationship cannot be ruled out. Numerous risk 
factors contribute to IHD, a portion of which is still not known. From the data currently present in the 
literature, H. pylori might contribute with two alternative pathways. First, it could participle in initial 
steps of formation of atherosclerotic plaque. Second, the bacterium could trigger the acute onset of IHD 
by stimulating platelet aggregation.  
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Legend  
Figure 1: a proposed model of interaction between Helicobacter pylori and cytokines in the induction of 
a procoagulative condition.  
